On Tuesday, Stoke Therapeutics Inc (NASDAQ: STOK) opened lower -9.79% from the last session, before settling in for the closing price of $9.70. Price fluctuations for STOK have ranged from $5.35 to $17.58 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 57.42% over the last five years. Company’s average yearly earnings per share was noted 26.79% at the time writing. With a float of $42.05 million, this company’s outstanding shares have now reached $54.03 million.
The firm has a total of 128 workers. Let’s measure their productivity. In terms of profitability, gross margin is 87.85%, operating margin of -277.31%, and the pretax margin is -243.42%.
Stoke Therapeutics Inc (STOK) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Stoke Therapeutics Inc is 22.99%, while institutional ownership is 88.06%. The most recent insider transaction that took place on May 02 ’25, was worth 228,543. In this transaction CHIEF MEDICAL OFFICER of this company sold 22,790 shares at a rate of $10.03, taking the stock ownership to the 33,998 shares. Before that another transaction happened on May 01 ’25, when Company’s CHIEF MEDICAL OFFICER sold 3,841 for $10.00, making the entire transaction worth $38,410. This insider now owns 56,788 shares in total.
Stoke Therapeutics Inc (STOK) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 26.79% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -0.71% during the next five years compared to 1.74% growth over the previous five years of trading.
Stoke Therapeutics Inc (NASDAQ: STOK) Trading Performance Indicators
Check out the current performance indicators for Stoke Therapeutics Inc (STOK). In the past quarter, the stock posted a quick ratio of 5.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 13.07.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.68, a number that is poised to hit 0.11 in the next quarter and is forecasted to reach -2.10 in one year’s time.
Technical Analysis of Stoke Therapeutics Inc (STOK)
Analysing the last 5-days average volume posted by the [Stoke Therapeutics Inc, STOK], we can find that recorded value of 0.7 million was lower than the volume posted last year of 0.87 million. As of the previous 9 days, the stock’s Stochastic %D was 50.56%. Additionally, its Average True Range was 0.65.
During the past 100 days, Stoke Therapeutics Inc’s (STOK) raw stochastic average was set at 37.63%, which indicates a significant decrease from 51.25% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 76.72% in the past 14 days, which was lower than the 77.00% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.03, while its 200-day Moving Average is $11.38. Now, the first resistance to watch is $9.51. This is followed by the second major resistance level at $10.26. The third major resistance level sits at $10.87. If the price goes on to break the first support level at $8.15, it is likely to go to the next support level at $7.54. Should the price break the second support level, the third support level stands at $6.79.
Stoke Therapeutics Inc (NASDAQ: STOK) Key Stats
There are currently 54,597K shares outstanding in the company with a market cap of 477.72 million. Presently, the company’s annual sales total 36,560 K according to its annual income of -88,980 K. Last quarter, the company’s sales amounted to 22,610 K and its income totaled -10,480 K.
